**(A)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Rank | 1 | 2 | 3 | 4 | 5 | 6 |
| Chemo | 0.00 | 0.00 | 0.02 | 0.09 | 0.26 | 0.62 |
| Camre-chemo | 0.14 | 0.19 | 0.22 | 0.21 | 0.16 | 0.08 |
| Pem-chemo | 0.10 | 0.16 | 0.21 | 0.24 | 0.20 | 0.09 |
| Sint-chemo | 0.26 | 0.27 | 0.20 | 0.14 | 0.09 | 0.05 |
| Nivo-chemo | 0.11 | 0.16 | 0.19 | 0.21 | 0.22 | 0.11 |
| Tori-chemo | 0.39 | 0.23 | 0.16 | 0.11 | 0.07 | 0.04 |

**(B)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Rank | 1 | 2 | 3 | 4 | 5 | 6 |
| Chemo | 0.00 | 0.00 | 0.01 | 0.08 | 0.28 | 0.63 |
| Camre-chemo | 0.30 | 0.25 | 0.21 | 0.14 | 0.06 | 0.03 |
| Pem-chemo | 0.12 | 0.17 | 0.22 | 0.30 | 0.13 | 0.06 |
| Sint-chemo | 0.28 | 0.29 | 0.22 | 0.13 | 0.06 | 0.03 |
| Nivo-chemo | 0.05 | 0.07 | 0.11 | 0.18 | 0.39 | 0.20 |
| Tori-chemo | 0.25 | 0.23 | 0.23 | 0.17 | 0.08 | 0.04 |

Supplementary File 4. Efficacy ranking data of (A) overall survival and (B) progression-free survival of each intervention. The order probability of pros and cons of each intervention is calculated using "Gemtc" package and "Rjags" package in R x64 4.1.3 softwares. The greater the value, the greater the probability of ranking. For overall survival, toripalimab plus chemotherapy ranked the first with the highest probability of 0.39, and sintilimab plus chemotherapy ranked the second. For progression-free survival, camrelizumab plus chemotherapy ranked first with the highest probability (0.30), followed by sintilimab plus chemotherap and toripalimab plus chemotherapy.